We are pleased to receive comments regarding our manuscript reporting transsynaptic retrograde degeneration (TRD) of retinal ganglion cells after infarction in various areas of the brain. We measured retinal nerve fiber layer (RNFL) thickness to indire…
Month: December 2013
Cross-linking improves visual acuity, reduces higher-order aberrations at 2 years
Collagen cross-linking provided good long-term visual, refractive and topographic outcomes in eyes treated for progressive keratoconus, a study found. The prospective case series included 42 eyes of 32 patients with progressive keratoconus and a mean a…
Abrams Royal Compounding Pharmacy initiates voluntary recall of drugs
Non-expired drug products produced and distributed for sterile use by Abrams Royal Compounding Pharmacy in Dallas are being voluntarily recalled, according to a press release from the U.S. Food and Drug Administration. Injectable medications, intraveno…
Carl Zeiss Meditec reports 5.2% revenue growth for fiscal year
Carl Zeiss Meditec reported revenue growth of 5.2%, to €906.4 million, for its fiscal year, according to a press release. Earnings before interest and tax increased to €133.9 million, compared with €122.9 million the previous year, and earnings per share rose to €1.15, compared with €0.88 reported last year, the release said.
VIDEO: TearScience CEO discusses latest news from company
Tim Willis, Co-founder and CEO of TearScience, discusses the latest updates from the company at the American Academy of Ophthalmology in New Orleans.
For the first time cells from the eye are inkjet printed
A group of researchers from the UK have used inkjet printing technology to successfully print cells taken from the eye for the very first time.
The brain’s data compression mechanisms
Researchers have hitherto assumed that information supplied by the sense of sight was transmitted almost in its entirety from its entry point to higher brain areas, across which visual sensation is generated.
Scientists develop new potential cure for rare eye disease
University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.
New optical device puts the power to detect retinal disease in the palm of a hand
A new optical device puts the power to detect eye disease in the palm of a hand. The tool-about the size of a hand-held video camera-scans a patient’s entire retina in seconds and could aid primary care physicians in the early detection of a host of re…
Lab Notes: It’s Yogurt — and an Ulcer Vaccine
(MedPage Today) — An oral vaccine for peptic ulcers — administered via yogurt culture — shows some promise. Also this week: light therapy for leukemia.
Mumbling Masculine Men; Avoid Eye Exams: That’s Improbable!
(MedPage Today) — A weekly report from our friends at Improbable Research.
Diabetes: Eyes Often Overlooked (CME/CE)
(MedPage Today) — A large proportion of people with diabetes mellitus are not getting the appropriate care to prevent visual impairment and blindness, a study reported. Clinicians need to speak up.
Diabetic macular edema: ‘not enough awareness and patient care’
Individuals with diabetes have a significantly higher risk of developing diabetic eye disease. But new research reveals that less than 50% of US adults with diabetic macular edema – retina swelling that can lead to blindness – are told by their doctor …
InSite releases positive results for phase 3 trial of BromSite
InSite Vision announced top-line results from its confirmatory phase 3 clinical trial of BromSite for the reduction of inflammation and pain after cataract surgery, according to a press release. The study included 248 patients who underwent cataract surgery in a two-arm trial to evaluate the efficacy and safety of BromSite (bromfenac 0.075% with DuraSite drug delivery technology) against the DuraSite vehicle alone. Patients were randomized and dosed twice a day 1 day before surgery, the day of surgery and 14 days after surgery.
Study: Patients with diabetes may not receive care to prevent visual impairment, blindness
Patients with diabetes mellitus in the U.S. report that they are not getting the prompt care needed to prevent visual impairment and blindness, according to a study. Seven hundred ninety-eight patients 40 years or older with diabetes mellitus and fundu…
BLOG: The cash flow benefits of continuity of care, part 3
Picking up where we left off last time regarding recall and continuity of care, let’s check in on how your practice is doing in this critical area. Take this simple test in your practice (assuming you are still using paper charts). Pull 20 charts at random, per doctor, of patients last seen 2 to 3 years ago (but not in the last year). Then fill out a chart that looks like this, with one line for each patient:
VIDEO: TearScience CEO discusses latest news from company
Tim Willis, Co-founder and CEO of TearScience, discusses the latest updates from the company at the American Academy of Ophthalmology in New Orleans.
People with diabetes at risk of developing diabetic macular edema during their lifetime
Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment,…
Alimera, FDA enter labeling discussions regarding Iluvien
Alimera Sciences and the U.S. Food and Drug Administration have begun discussing labeling for the Iluvien implant, and as a result, the company is not required to participate in the Dermatologic and Ophthalmic Drugs Advisory Committee meeting scheduled…
Correlation between pseudodrusen, geographic atrophy progression indicates process leading to atrophy
The strong spatiotemporal correlation between reticular pseudodrusen and geographic atrophy progression in dry age-related macular degeneration suggests that they are early indicators leading to atrophy, according to a study.One hundred twenty-six eyes of 92 patients with dry AMD and geographic atrophy who underwent sequential fundus autofluorescence and/or near infrared reflectance imaging were included in the retrospective study. Patients were followed for an average of 20.4 months.